The demo achieved both of those its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and superior improvements in liver fibrosis with no worsening of steatohepatitis, along with resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparison to placebo.1What's this? Verify "Rec